Effects of Growth Hormone Treatment on B-type Natriuretic Peptide as a Marker of Heart Failure in Adults with Growth Hormone Deficiency

Abstract

Objective: Patients with growth hormone deficiency (GHD) have abnormalities of cardiac structure and function. Growth hormone replacement (GHR) therapy can induce an increase in cardiac mass and improvement in left ventricular ejection fraction. B-type natriuretic peptide (BNP) levels have been successfully used to identify patients with heart failure and they correlate with both disease severity and prognosis. Design: To investigate the effect of growth hormone replacement on BNP and inflammatory cardiovascular risk factors in adults with GHD we determined NT-proBNP and high sensitive C-reactive protein (CrP) before, 6 and 12 months after GHR. Patients: Thirty adults (14 males, 16 females) with GHD mean age: 41.7±14.5 years (range: 17.2 to 75.4 years) were recruited from the German KIMS cohort (Pfizer's International Metabolic Database). Results: During 12 months of GHR, a significant increase of IGF-1 (85.4±72.1 vs. 172.0±98 μg/dl; p=0.0001; IGF-1 SDS mean±SD: -3.85±3.09 vs. -0.92±1.82) was detectable. Mean baseline NT-proBNP was 112±130 pg/ml (range: 7 to 562). Twelve patients had normal BNP, whereas 18 revealed NT-proBNP values corresponding to those of patients with heart failure NYHA classification I (n=10), NYHA II (n=6) and NYHA III (n=2), respectively. Baseline BNP levels correlated significantly (p=0.044) with increased baseline CrP values. After 12 months of GHR, a significant decrease (p=0.001) in NT-proBNP levels mean: 68±81 pg/ml (range: 5 to 395) was detectable, associated with an improvement in NYHA performance status in 10 of the 18 with increased baseline NT-proBNP. Conclusions: Based on our study, approximately two-thirds of patients with GHD have increased NT-proBNP levels which may be useful as screening/diagnostic laboratory parameter for heart failure in such patients. GHR therapy decreases BNP levels in most patients with GHD.

Growth hormone deficiency - heart failure - BNP - IGF-1

References

• 1 Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism.  Lancet. 1990;  336 285-288
• 2 Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism.  Clin Endocrinol (Oxf). 1997;  46 75-81
• 3 Wuster C, Slenczka E, Ziegler R. Increased prevalence of osteoporosis and arteriosclerosis in conventionally substituted anterior pituitary insufficiency: need for additional growth hormone substitution?.  Klin Wochenschr. 1991;  69 769-773
• 4 Markussis V, Beshyah SA, Fisher C, Sharp P, Nicolaides AN, Johnston DG. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults.  Lancet. 1992;  340 1188-1192
• 5 Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults.  J Clin Endocrinol Metab. 1999;  84 453-457
• 6 Evans LM, Davies JS, Goodfellow J, Rees JA, Scanlon MF. Endothelial dysfunction in hypopituitary adults with growth hormone deficiency.  Clin Endocrinol (Oxf). 1999;  50 457-464
• 7 Capaldo B, Patti L, Oliviero U, Longobardi S, Pardo F, Vitale F. et al . Increased arterial intima-media thickness in childhood-onset growth hormone deficiency.  J Clin Endocrinol Metab. 1997;  82 1378-1381
• 8 Beshyah SA, Johnston DG. Cardiovascular disease and risk factors in adults with hypopituitarism.  Clin Endocrinol (Oxf). 1999;  50 1-15
• 9 Cuneo RC, Salomon F, McGauley GA, Sonksen PH. The growth hormone deficiency syndrome in adults.  Clin Endocrinol (Oxf). 1992;  37 387-397
• 10 De Boer H, Blok GJ, Voerman HJ, De Vries PM, van der Veen EA. Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance analysis.  J Clin Endocrinol Metab. 1992;  75 833-837
• 11 Binnerts A, Deurenberg P, Swart GR, Wilson JH, Lamberts SW. Body composition in growth hormone-deficient adults.  Am J Clin Nutr. 1992;  55 918-923
• 12 Weaver JU, Monson JP, Noonan K, John WG, Edwards A, Evans KA. et al . The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults.  J Clin Endocrinol Metab. 1995;  80 153-159
• 13 Johansson JO, Fowelin J, Landin K, Lager I, Bengtsson BA. Growth hormone-deficient adults are insulin-resistant.  Metabolism. 1995;  44 1126-1129
• 14 Rosen T, Eden S, Larson G, Wilhelmsen L, Bengtsson BA. Cardiovascular risk factors in adult patients with growth hormone deficiency.  Acta Endocrinol Copenh. 1993;  129 195-200
• 15 Johansson JO, Landin K, Johannsson G, Tengborn L, Bengtsson BA. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.  Thromb Haemost. 1996;  76 422-428
• 16 Vasan RS, Sullivan LM, D'Agostino RB, Roubenoff R, Harris T, Sawyer DB, Levy D, Wilson PW. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study.  Ann Intern Med. 2003;  139 642-648
• 17 Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study.  Circulation. 2002;  106 939-944
• 18 Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor 1 (IGF-1) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study.  J Clin Endocrinol Metab. 2004;  89 114-120
• 19 Heald AH, Anderson SG, Ivison F, Laing I, Gibson JM, Cruickshank K. C-reactive protein and the insulin-like growth factor (IGF)-system in relation to risk of cardiovascular disease in different ethnic groups.  Atherosclerosis. 2003;  170 79-86
• 20 Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart (Review).  Clin Endocrinol (Oxf). 2001;  54 137-154
• 21 Colao A, Vitale G, Pivonello R, Ciccarelli A, Di Somma C, Lombardi G. The heart: an end-organ of GH action (Review).  Eur J Endocrinol. 2004;  151 ((Suppl 1)) S93-S101
• 22 Colao A, Di Somma C, Cuocolo A, Filippella M, Rota F, Acampa W, Savastano S, Salvatore M, Lombardi G. The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study.  J Clin Endocrinol Metab. 2004;  89 5998-6004
• 23 Colao A, Cuocolo A, Di Somma C, Cerbone G, Morte AM, Pivonello R, Nicolai E, Salvatore M, Lombardi G. Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study.  Clin Endocrinol (Oxf). 2000;  52 447-455
• 24 Colao A, Cuocolo A, Di Somma C, Cerbone G, Della Morte AM, Nicolai E, Lucci R, Salvatore M, Lombardi G. Impaired cardiac performance in elderly patients with growth hormone deficiency.  J Clin Endocrinol Metab. 1999;  84 3950-3955
• 25 Colao A, di Somma C, Cuocolo A, Spinelli L, Tedesco N, Pivonello R, Bonaduce D, Salvatore M, Lombardi G. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency.  J Clin Endocrinol Metab. 2001;  86 1874-1881
• 26 Colao A, di Somma C, Pivonello R, Cuocolo A, Spinelli L, Bonaduce D, Salvatore M, Lombardi G. The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study.  J Clin Endocrinol Metab. 2002;  87 1088-1093
• 27 Colao A, Di Somma C, Salerno M, Spinelli L, Orio F, Lombardi G. The cardiovascular risk of GH-deficient adolescents.  J Clin Endocrinol Metab. 2002;  87 3650-3655
• 28 Salerno M, Esposito V, Spinelli L, Di Somma C, Farina V, Muzzica S, De Horatio LT, Lombardi G, Colao A. Left ventricular mass and function in children with GH deficiency before and during 12 months GH replacement therapy.  Clin Endocrinol (Oxf). 2004;  60 630-636
• 29 Cuocolo A, Nicolai E, Colao A, Longobardi S, Cardei S, Fazio S, Merola B, Lombardi G, Saccà L, Salvatore M. Improved left ventricular function after growth hormone replacement in patients with hypopituitarism: assessment with radionuclide angiography.  Eur J Nucl Med. 1996;  23 390-394
• 30 Ezzat S, Fear S, Gaillard RC, Gayle C, Landy H, Marcovitz S, Mattioni T, Nussey S, Rees A, Svanberg E. Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement after GH replacement in GH-deficient adults.  J Clin Endocrinol Metab. 2002;  87 2725-2733
• 31 Ter Maaten J, De Boer H, Kamp O, Stuurman L, Van der Veen E. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency.  J Clin Endocrinol Metab. 1999;  84 2373-2380
• 32 Gibney J, Wallace JD, Spinks T, Schnorr L, Ranicar A, Cuneo RC, Lockhart S, Burnand KG, Salomon F, Sonksen PH, Russell-Jones D. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients.  J Clin Endocrinol Metab. 1999;  84 2596-2602
• 33 Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis.  Circulation. 2003;  108 2648-2652
• 34 Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain.  Nature. 1988;  332 78-81
• 35 Pfister R, Schneider CA. Natriuretic peptides BNP and NT-pro-BNP: established laboratory markers in clinical practice or just perspectives?.  Clin Chim Acta. 2004;  349 25-38
• 36 Rodeheffer RJ. Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004?.  J Am Coll Cardiol. 2004;  18 740-749
• 37 Wieczorek SJ, Wu AH, Christenson R, Krishnaswamy P, Gottlieb S, Rosano T, Hager D, Gardetto N, Chiu A, Bailly KR, Maisel A. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation.  Am Heart J. 2002;  144 834-839
• 38 Bengtsson BA, Abs R, Bennmarker H, Monson JP, Feldt-Rasmussen U, Hernberg-Stahl E, Westberg B, Wilton P, Wuster C. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board.  J Clin Endocrinol Metab. 1999;  84 3929-3935
• 39 Abs R, Bengtsson BA, Hernberg-Stahl E, Monson JP, Tauber JP, Wilton P, Wuster C. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety.  Clin Endocrinol (Oxf). 1999;  50 703-713
• 40 Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency.  J Clin Endocrinol Metab. 1998;  83 379-381
• 41 Aimaretti G, Baffoni C, DiVito L, Bellone S, Grottoli S, Maccario M, Arvat E, Camanni F, Ghigo E. Comparisons among old and new provocative tests of GH secretion in 178 normal adults.  Eur J Endocrinol. 2000;  142 347-352
• 42 Barnes SC. Ann Clin Biochem. 2004;  41 459-463
• 43 Richards M, Troughton RW. NT-proBNP in heart failure: therapy decisions and monitoring.  Eur J Heart Fail. 2004;  6 351-354
• 44 Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.  JAMA. 2005;  293 1609-1616
• 45 Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp BE, Neal BC, Patel A, MacMahon SW. Prediction of Heart Failure by Amino Terminal-pro-B-Type Natriuretic Peptide and C-Reactive Protein in Subjects With Cerebrovascular.  Disease Hypertension. 2005;  45 69-74

1 Study Sponsor
The German KIMS board provided support for the random assignment of patients, and partial grant support for the determination of plasma samples.

Correspondence